stockportfolio.pro
Stocks / LEGN vs LQDA
LEGN vs LQDA
Legend Biotech Corporation and Liquidia Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Legend Biotech Corporation (LEGN) | Liquidia Corporation (LQDA) | |
|---|---|---|
| Market cap | $6.5B | $6.2B |
| Revenue (latest FY) | $1.03B | $158.32M |
| Net income (latest FY) | $-296.80M | $-68.92M |
| Revenue growth (5y CAGR) | 106.4% | 192.5% |
| Net margin | -28.8% | -43.5% |
| Return on equity | -29.6% | -154.0% |
| P/E ratio | — | 410.7 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open LEGN — free Open LQDA — freeFrequently asked questions
Which is bigger, LEGN or LQDA?
Legend Biotech Corporation is larger by market capitalization — $6.5B versus $6.2B.
Which grows faster, LEGN or LQDA?
Over the last five fiscal years, Liquidia Corporation grew revenue faster — 192.5%/yr versus 106.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.